3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
33
Lung Neoplasms
13
Breast Neoplasms
12
Colorectal Neoplasms
11
Ovarian Neoplasms
10
Recurrence
9
Neoplasms
9
Small Cell Lung Carcinoma
8
Neoplasm Metastasis
8
Head and Neck Neoplasms
8
Urinary Bladder Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
7
Lymphoma, Large B-Cell, Diffuse
7
Prostatic Neoplasms
6
Carcinoma, Hepatocellular
6
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
5
Diabetes Mellitus, Insulin-Dependent, 12
5
Carcinoma
5
Multiple Myeloma
4
Lymphoma, Follicular
4
Cholangiocarcinoma
4
Uterine Cervical Neoplasms
3
Recurrent Squamous Cell Lung Carcinoma
3
Oropharyngeal Neoplasms
3
Mouth Neoplasms
3
Mesothelioma
3
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Kidney Neoplasms
3
Interventions
blinatumomab
4
Rituximab
4
Cyclophosphamide
3
ponatinib
2
Vorinostat
2
Vincristine
2
Prednisone
2
Ifosfamide
2
Etoposide
2
Doxorubicin
2
Brentuximab Vedotin
2
Bortezomib
2
tetulomab tetraxetan lu-177
1
pembrolizumab
1
pegaspargase
1
ibrutinib
1
ibritumomab tiuxetan
1
durvalumab
1
cobomarsen
1
asparaginase erwinia chrysanthemi recombinant
1
acalabrutinib
1
Methotrexate
1
Melphalan
1
Lutetium
1
Lenalidomide
1
KW-2478
1
Imatinib Mesylate
1
Hsp90 inhibitor KU757
1
Dexamethasone
1
Daunorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Immunoproliferative Disorders
×
durvalumab
×
Clear all
NCT02733042
2023-11-18
FUSION NHL 001
Celgene
Phase 1/2
Completed
106 enrolled
48 charts